JP5677096B2 - 急性腎障害を予防および治療するための方法 - Google Patents

急性腎障害を予防および治療するための方法 Download PDF

Info

Publication number
JP5677096B2
JP5677096B2 JP2010547861A JP2010547861A JP5677096B2 JP 5677096 B2 JP5677096 B2 JP 5677096B2 JP 2010547861 A JP2010547861 A JP 2010547861A JP 2010547861 A JP2010547861 A JP 2010547861A JP 5677096 B2 JP5677096 B2 JP 5677096B2
Authority
JP
Japan
Prior art keywords
subject
peptide
acid
kidney
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010547861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513241A (ja
JP2011513241A5 (enExample
Inventor
ヘイゼル エイチ セトー
ヘイゼル エイチ セトー
ダイアン フェルゼン
ダイアン フェルゼン
Original Assignee
コーネル ユニヴァーシティー
コーネル ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, コーネル ユニヴァーシティー filed Critical コーネル ユニヴァーシティー
Publication of JP2011513241A publication Critical patent/JP2011513241A/ja
Publication of JP2011513241A5 publication Critical patent/JP2011513241A5/ja
Application granted granted Critical
Publication of JP5677096B2 publication Critical patent/JP5677096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010547861A 2008-02-26 2009-02-25 急性腎障害を予防および治療するための方法 Active JP5677096B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3158508P 2008-02-26 2008-02-26
US61/031,585 2008-02-26
PCT/US2009/035132 WO2009108695A2 (en) 2008-02-26 2009-02-25 Methods for prevention and treatment of acute renal injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014263863A Division JP2015063561A (ja) 2008-02-26 2014-12-26 急性腎障害を予防および治療するための方法

Publications (3)

Publication Number Publication Date
JP2011513241A JP2011513241A (ja) 2011-04-28
JP2011513241A5 JP2011513241A5 (enExample) 2012-04-12
JP5677096B2 true JP5677096B2 (ja) 2015-02-25

Family

ID=41013650

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010547861A Active JP5677096B2 (ja) 2008-02-26 2009-02-25 急性腎障害を予防および治療するための方法
JP2014263863A Pending JP2015063561A (ja) 2008-02-26 2014-12-26 急性腎障害を予防および治療するための方法
JP2016087350A Pending JP2016175924A (ja) 2008-02-26 2016-04-25 急性腎障害を予防および治療するための方法
JP2017179838A Pending JP2017226697A (ja) 2008-02-26 2017-09-20 急性腎障害を予防および治療するための方法
JP2018241524A Pending JP2019059785A (ja) 2008-02-26 2018-12-25 急性腎障害を予防および治療するための方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014263863A Pending JP2015063561A (ja) 2008-02-26 2014-12-26 急性腎障害を予防および治療するための方法
JP2016087350A Pending JP2016175924A (ja) 2008-02-26 2016-04-25 急性腎障害を予防および治療するための方法
JP2017179838A Pending JP2017226697A (ja) 2008-02-26 2017-09-20 急性腎障害を予防および治療するための方法
JP2018241524A Pending JP2019059785A (ja) 2008-02-26 2018-12-25 急性腎障害を予防および治療するための方法

Country Status (7)

Country Link
US (9) US8143219B2 (enExample)
EP (3) EP3243521B1 (enExample)
JP (5) JP5677096B2 (enExample)
CN (4) CN107802821A (enExample)
DK (1) DK2262520T3 (enExample)
HK (1) HK1202429A1 (enExample)
WO (1) WO2009108695A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015063561A (ja) * 2008-02-26 2015-04-09 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
EP3725324A1 (en) 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
SI3708178T1 (sl) * 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
EP3603658B1 (en) 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2519249A4 (en) 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
US8382672B2 (en) * 2010-03-12 2013-02-26 Claire Andrews Macro/micro duty cycle devices, systems, and methods employing low-frequency ultrasound or other cyclical pressure energies
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP2013532124A (ja) * 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
NZ613671A (en) * 2010-12-31 2017-01-27 Zeus Scientific Inc Improved methods for determining cell viability using molecular nucleic acid-based techniques
EP3108975A1 (en) * 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
US20120315281A1 (en) * 2011-05-13 2012-12-13 The Penn State Research Foundation Treatment of renal injury
WO2013021093A1 (es) * 2011-08-10 2013-02-14 Digna Biotech, S.L. Uso de la cardiotofina-1 para el tratamiento de enfermedades renales
CN107496899A (zh) * 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CN107261380A (zh) * 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途
US9353171B2 (en) 2011-11-17 2016-05-31 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
CA2858550A1 (en) 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2865409C (en) * 2012-02-23 2020-07-21 Cornell University Aromatic-cationic peptides and uses of same
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
EP4397314B1 (en) * 2012-10-22 2025-12-03 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) * 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015089316A1 (en) * 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
US10905818B2 (en) * 2014-03-31 2021-02-02 Zoll Medical Corporation Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome
HUE054626T2 (hu) 2014-06-25 2021-09-28 Flamma Spa Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
PL3160985T3 (pl) 2014-06-30 2021-12-27 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylo-l-fenyloalaninoamidu
US10744178B2 (en) 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
JP6946342B2 (ja) * 2016-05-09 2021-10-06 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ エバンスブルー誘導体の化学的コンジュゲート、ならびに放射線治療剤およびイメージング剤としてのそれらの使用
CN107644976B (zh) * 2016-07-22 2020-09-29 清华大学 锂离子电池电极
EP3525771A4 (en) * 2016-11-21 2020-05-27 Saghmos Therapeutics, Inc. PREVENTION AND / OR TREATMENT OF ACUTE RENAL FAILURE INDUCED BY CONTRAST AGENTS
EP3692032B1 (en) 2017-10-03 2024-06-19 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
WO2019165200A1 (en) 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
WO2020018381A1 (en) * 2018-07-18 2020-01-23 The Regents Of The University Of California Kidney injury treatment
CN109946139A (zh) * 2019-02-28 2019-06-28 东南大学 一种石蜡切片免疫组化套染pas试剂盒及其染色方法和应用
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
WO2020214518A1 (en) * 2019-04-18 2020-10-22 Arcuate Therapeutics, Inc. Methods of treating renal conditions using peptides that improve mitochondrial function
CN110250110A (zh) * 2019-07-11 2019-09-20 南京医科大学附属逸夫医院 一种顺铂所致急性肾损伤的小鼠模型的构建方法
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN113209294B (zh) * 2020-02-05 2023-06-13 复旦大学 Dor激动剂在制备对抗肾脏纤维化药物中的应用
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
AU2021253243B2 (en) * 2020-04-08 2024-01-18 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
KR102308991B1 (ko) 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
CN111933006B (zh) * 2020-07-30 2022-06-03 四川大学华西医院 一种模拟巨噬细胞改善小鼠急性肾损伤实验的方法及系统
US11389431B2 (en) 2020-09-09 2022-07-19 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
WO2022056378A1 (en) * 2020-09-11 2022-03-17 Renibus Therapeutics, Inc. Method for treating cancer with kidney protection
WO2022159382A1 (en) 2021-01-19 2022-07-28 The Trustees Of Columbia University In The City Of New York Reactivation of mtor in acute kidney injury (aki)
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN119215059B (zh) * 2023-06-28 2026-05-26 兰州大学 右磷丝氨酸在用于制备预防和/或治疗肾损伤药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
WO1994028012A1 (en) * 1993-05-28 1994-12-08 Warner-Lambert Company Hydroxamate inhibitors of endothelin converting enzyme
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6503713B1 (en) 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
PT1263464E (pt) 2000-03-09 2012-12-17 Genzyme Corp Utilização de anticorpos anti-tgf-beta antagonistas para tratar ou para prevenir a perda da função renal
ATE496533T1 (de) 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
CA2447008A1 (en) 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
EP3725324A1 (en) 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
CN107802821A (zh) 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015063561A (ja) * 2008-02-26 2015-04-09 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法

Also Published As

Publication number Publication date
EP3243521A1 (en) 2017-11-15
JP2011513241A (ja) 2011-04-28
US20230398172A1 (en) 2023-12-14
US11628198B2 (en) 2023-04-18
JP2015063561A (ja) 2015-04-09
JP2019059785A (ja) 2019-04-18
US20150353602A1 (en) 2015-12-10
US8940696B2 (en) 2015-01-27
US20130017150A1 (en) 2013-01-17
WO2009108695A2 (en) 2009-09-03
CN107802821A (zh) 2018-03-16
DK2262520T3 (en) 2017-08-07
EP3741381B1 (en) 2024-04-24
JP2017226697A (ja) 2017-12-28
CN106975070A (zh) 2017-07-25
WO2009108695A3 (en) 2009-12-30
EP3243521B1 (en) 2020-05-27
US20190388492A1 (en) 2019-12-26
JP2016175924A (ja) 2016-10-06
EP2262520A4 (en) 2012-02-29
US8592373B2 (en) 2013-11-26
US20180177840A1 (en) 2018-06-28
CN101951936A (zh) 2011-01-19
US20170112893A1 (en) 2017-04-27
US8143219B2 (en) 2012-03-27
CN104056248A (zh) 2014-09-24
US20090221514A1 (en) 2009-09-03
US20140107033A1 (en) 2014-04-17
HK1202429A1 (en) 2015-10-02
EP2262520A2 (en) 2010-12-22
EP2262520B1 (en) 2017-05-03
US20210023161A1 (en) 2021-01-28
EP3741381A1 (en) 2020-11-25
HK1246673A1 (en) 2018-09-14

Similar Documents

Publication Publication Date Title
US20230398172A1 (en) Methods for prevention and treatment of acute renal injury
Chander et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen
JP6271785B2 (ja) 代謝性症候群を予防し又は治療するための方法
Schnellmann Toxic responses of the kidney
JP6319738B2 (ja) 虚血／再灌流障害に続くノーリフローの予防又は処置方法
US20180344814A1 (en) Peptide therapeutics and methods for using same
Castino et al. Autophagy‐dependent cell survival and cell death in an autosomal dominant familial neurohypophyseal diabetes insipidus in vitro model
JP2014522879A (ja) 腎疾患の治療のためのカルジオトロフィン−１の使用
CA2560902A1 (en) Treatment of neurological conditions using complement c5a receptor modulators
HK1235712A1 (en) Methods for prevention and treatment of acute renal injury
HK1246673B (en) A peptide for use for prevention and treatment of acute renal injury
Henderson et al. MP060 EXISTENCE OF THE AUTOREACTIVE T CELLS FOUND IN GOODPASTURE’S DISEASE IS ACCOUNTABLE BY PROPERTIES OF ENDOSOMAL PROCESSING
Bieniaś et al. Post-inflammatory nephropathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141226

R150 Certificate of patent or registration of utility model

Ref document number: 5677096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250